Prulacabtagene leucel (prula-cel, ADI-001)
B-cell mediated Autoimmune Diseases (e.g., Systemic Lupus Erythematosus)
Key Facts
About Adicet Bio
Adicet Bio is focused on delivering best-in-class, allogeneic gamma delta T cell therapies, offering a potentially superior alternative to traditional alpha beta CAR-T. Its proprietary platform harnesses the innate tissue-homing, MHC-independent tumor recognition, and favorable safety profile of gamma delta 1 T cells to target both solid tumors and autoimmune diseases. The company is publicly traded and is advancing its lead program, prula-cel, through clinical development with a focus on achieving key milestones in 2026.
View full company profileAbout Adicet Bio
Adicet Bio is focused on delivering best-in-class, allogeneic gamma delta T cell therapies, offering a potentially superior alternative to traditional alpha beta CAR-T. Its proprietary platform harnesses the innate tissue-homing, MHC-independent tumor recognition, and favorable safety profile of gamma delta 1 T cells to target both solid tumors and autoimmune diseases. The company is publicly traded and is advancing its lead program, prula-cel, through clinical development with a focus on achieving key milestones in 2026.
View full company profile